XtalPi Inc. is a pharmaceutical technology company based in Cambridge, Massachusetts, with additional offices in China. Founded in 2014 by a team of quantum physicists from MIT, XtalPi focuses on transforming drug research and development through its Intelligent Digital Drug Discovery and Development (ID4) platform. This platform integrates quantum mechanics, artificial intelligence, and high-performance cloud computing to enhance the efficiency and accuracy of drug R&D processes. XtalPi's offerings include advanced tools for crystal structure prediction and determination, solid state testing, small molecule drug design, and AI model development. The company aims to accelerate drug discovery and development, thereby contributing to global health improvements. Its innovative technologies have garnered recognition within the industry and facilitated strategic partnerships with leading pharmaceutical companies.
Xellar Biosystems is a biotechnology company that focuses on enhancing drug discovery and development through the integration of artificial intelligence and machine learning. The company offers a research platform that combines advanced computational methods with large-scale wet-lab experiments. This approach allows researchers to utilize simplified models and reductionistic tools, streamlining the processes of drug testing and treatment analysis. By leveraging these technologies, Xellar Biosystems aims to accelerate the development of new pharmaceuticals, ultimately contributing to more efficient and effective healthcare solutions.
Newdel Biotech specializes in drug screening services and the development of innovative biomedical technologies. The company focuses on creating advanced drugs specifically aimed at treating tumors, utilizing DNA Encoded Library technology to enhance the success rates of these treatments. This innovative approach aims to provide tumor patients with next-generation alternative medicines, improving their therapeutic options and outcomes. In addition to drug development, Newdel Biotech also offers consulting services in the biomedical technology sector, contributing to advancements in healthcare solutions.
META Pharmaceuticals is a drug development company focused on creating innovative treatments for autoimmune diseases. The company specializes in the emerging field of immunometabolism, aiming to develop first-in-class drugs that address these conditions. By integrating artificial intelligence with biomedical research, META Pharmaceuticals enhances its ability to analyze and validate new therapeutic targets and their mechanisms of action. This approach accelerates the discovery of targets and facilitates their translation into effective new therapies.
Merda Biopharma is a AI-enabled drug discovery technology platform that produces small molecule drugs that helps immune metabolism.
Alternative Bio
Corporate Round in 2025
Alternative Bio is a biotechnology company focused on developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes.
Orient Biotech
Venture Round in 2025
Orient Biotech is a private biotechnology company developing innovative drugs for underappreciated modified processing enzymes.
Developer and researcher of novel tumor immunotherapy drugs intended to serve the biotechnology. The company focuses on new tumor immunotherapy drugs based on immunometabolic reprogramming & artificial intelligence (AI), its team has developed the world's first Meta 10 immune metabolism reprogramming technology and established a technology platform for the discovery, development, and production of biological macromolecular drugs and new immune cell drugs.
ReviR Therapeutics is a genomics-focused company that develops innovative RNA-based medicines aimed at treating cancer, rare genetic disorders, and infectious diseases. The company leverages an artificial intelligence-driven platform to enhance the discovery of therapeutics that target human RNAs. By combining advanced computational techniques with genomic insights, ReviR Therapeutics strives to create transformative therapies that can significantly impact patient care and improve health outcomes for millions.
Developer and researcher of novel tumor immunotherapy drugs intended to serve the biotechnology. The company focuses on new tumor immunotherapy drugs based on immunometabolic reprogramming & artificial intelligence (AI), its team has developed the world's first Meta 10 immune metabolism reprogramming technology and established a technology platform for the discovery, development, and production of biological macromolecular drugs and new immune cell drugs.
Aoshixin
Seed Round in 2024
Aoshixin is a clock chip developer that specializes in the research and development of high-precision, high-reliability clock chips and other related products. Its goods find application in industries such as high-reliability and scientific research devices.
META Pharmaceuticals is a drug development company focused on creating innovative treatments for autoimmune diseases. The company specializes in the emerging field of immunometabolism, aiming to develop first-in-class drugs that address these conditions. By integrating artificial intelligence with biomedical research, META Pharmaceuticals enhances its ability to analyze and validate new therapeutic targets and their mechanisms of action. This approach accelerates the discovery of targets and facilitates their translation into effective new therapies.
PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, focused on identifying new druggable targets for cancer and other unmet diseases. Since its incorporation in 2014, the company has developed Site-Seeker, a platform that uncovers cryptic druggable sites within the human genome and connects them to therapeutic functions in live-cell contexts. This innovative approach allows PhoreMost to design small molecule drugs based on functionally validated protein fragments. By collaborating with a global network of academic and industrial partners, the company aims to bring novel targeted therapies to market more efficiently, ultimately benefiting patients through cost savings and the development of first-in-class drug discovery programs for potential licensing to pharmaceutical companies.
Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.